Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/24/2025

Cross-Taper Protocol from Sertraline to Fluvoxamine for OCD

Rationale for the Switch

  • Higher SSRI doses are necessary for OCD compared to depression or anxiety disorders, with greater efficacy at higher doses 1

Critical Safety Considerations

  • The overlap period creates potential for serotonin syndrome, particularly when combining SSRIs, monitor closely for symptoms such as fever, confusion, agitation, tremor, hyperreflexia, myoclonus, diaphoresis, and tachycardia 2
  • Benzodiazepines, such as alprazolam and triazolam, may require dose reduction due to fluvoxamine's potent CYP1A2 inhibition and moderate CYP3A4 inhibition 2

Expected Timeline for Response

  • Assess therapeutic benefit at 12 weeks minimum, as OCD requires prolonged treatment duration at effective doses 1
  • If inadequate response at 300mg after 12 weeks, consider augmentation strategies rather than further dose escalation 1

Long-Term Management

  • Once remission is achieved, continue treatment for 12-24 months minimum due to high relapse risk 1
  • Consider adding cognitive-behavioral therapy with exposure and response prevention if response remains inadequate 1

REFERENCES

1

Treatment of Obsessive-Compulsive Disorder [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025